International Journal For Multidisciplinary Research
E-ISSN: 2582-2160
•
Impact Factor: 9.24
A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal
Home
Research Paper
Submit Research Paper
Publication Guidelines
Publication Charges
Upload Documents
Track Status / Pay Fees / Download Publication Certi.
Editors & Reviewers
View All
Join as a Reviewer
Reviewer Referral Program
Get Membership Certificate
Current Issue
Publication Archive
Conference
Publishing Conf. with IJFMR
Upcoming Conference(s) ↓
WSMCDD-2025
GSMCDD-2025
Conferences Published ↓
RBS:RH-COVID-19 (2023)
ICMRS'23
PIPRDA-2023
Contact Us
Plagiarism is checked by the leading plagiarism checker
Call for Paper
Volume 7 Issue 1
January-February 2025
Indexing Partners
Physiological and Pathological Hypertrophic Cardiomyopathy
Author(s) | Haritha Chatla, Guddanti Hema, Gayathri Paturi, C.K.Gopavarapu, Raja Shekar Perusomula |
---|---|
Country | India |
Abstract | Hypertrophic cardiomyopathy (HCM) refers to the abnormal thickening of the heart muscle, primarily affecting the left ventricle, and can occur due to both physiological and pathological causes. Physiological hypertrophy is an adaptive, reversible response to increased physical demand, as seen in athletes or pregnancy. It is characterized by proportional thickening of the ventricular walls, increased chamber size, and enhanced cardiac function, without fibrosis or myocyte disarray. This form of hypertrophy is beneficial and reversible when the increased workload is reduced, posing minimal health risks.In contrast, pathological hypertrophy arises due to genetic mutations or chronic conditions such as hypertension and hypertrophic cardiomyopathy. It often results in asymmetric thickening, particularly of the interventricular septum, and can lead to left ventricular outflow tract obstruction (LVOTO). Pathological hypertrophy is accompanied by fibrosis, myocyte disarray, and impaired diastolic function, which can progress to heart failure, arrhythmias, or sudden cardiac death. Unlike physiological hypertrophy, pathological forms are typically irreversible and associated with significant morbidity and mortality. The Physiological hypertrophy enhances cardiac performance and is reversible, pathological hypertrophy leads to adverse outcomes and requires medical intervention. Differentiating between these forms is particularly important in athletes and individuals with a family history of heart disease to prevent potential complications. |
Keywords | Hypertrophic cardiomyopathy, Mavacamten, Physiological hypertrophy, Pathological hypertrophy, Beta blockers, Endocarditis |
Field | Medical / Pharmacy |
Published In | Volume 7, Issue 1, January-February 2025 |
Published On | 2025-01-26 |
Cite This | Physiological and Pathological Hypertrophic Cardiomyopathy - Haritha Chatla, Guddanti Hema, Gayathri Paturi, C.K.Gopavarapu, Raja Shekar Perusomula - IJFMR Volume 7, Issue 1, January-February 2025. DOI 10.36948/ijfmr.2025.v07i01.34963 |
DOI | https://doi.org/10.36948/ijfmr.2025.v07i01.34963 |
Short DOI | https://doi.org/g829ss |
Share this
E-ISSN 2582-2160
doi
CrossRef DOI is assigned to each research paper published in our journal.
IJFMR DOI prefix is
10.36948/ijfmr
Downloads
All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.